PAS-393 / Pascal Biosci - LARVOL DELTA

Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment (Businesswire) - "Pascal Biosciences Inc...and SōRSE Technology Corporation...have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the cannabinoid PAS-393 towards clinical testing against cancer...'We are on track to enter our first clinical trial with Pascal within a year'...Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SōRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor."

New P1 trial • Oncology